News

FDA approves alogliptin, alone and in combinations

Publish date: January 28, 2013

 

a.ault@elsevier.com

Twitter @aliciaault

Pages

Recommended Reading

Ranbaxy Recalls Atorvastatin
MDedge Endocrinology
PCSK9 Antibodies Safely Cut LDL in Phase II
MDedge Endocrinology
Statins' Diabetogenic Impact Influenced by Underlying Risks
MDedge Endocrinology
Fatty Liver Disease: The Silent Epidemic
MDedge Endocrinology
Bariatric surgery cut vascular events in diabetes
MDedge Endocrinology
FDA panel backs approval of canagliflozin for type 2 diabetes
MDedge Endocrinology
SSRIs for PTSD bring cardiometabolic benefits
MDedge Endocrinology
How to prevent 1 million coronary events
MDedge Endocrinology
Metabolic syndrome skews Oncotype DX reliability
MDedge Endocrinology
HDL-raising: A good hypothesis gone bad
MDedge Endocrinology